Health and Healthcare
BioNTech Raises Over $400 Million to Boost COVID-19 Efforts
Published:
Last Updated:
BioNTech S.E. (NASDAQ: BNTX) has been one of the leading companies in the race to a COVID-19 vaccine. Its partnership with Pfizer Inc. (NYSE: PFE) has brought BioNTech to the top, with its shares rising over 160% year to date. Now, it’s time to capitalize.
The company announced a secondary offering of 5,000,000 American depositary shares (ADSs), each representing one ordinary share, with an overallotment option to purchase an additional 750,000 ADSs.
The underwriters for the offering are JPMorgan, BofA Securities, Berenberg, UBS, Canaccord Genuity, Commerzbank, Wolfe Capital Markets and Bryan Garnier.
Certain new and existing investors, including Pfizer, have indicated an interest in purchasing up to an aggregate of $200 million in ADSs. However, these indications of interest are not binding agreements or commitments to purchase.
The pricing for the offering has yet to be determined. With shares already posting a massive gain this year, BioNTech will make a nice chunk of change to put toward its research and operations.
At the most recent closing price of $88.20, the entire offering would be valued up to $441 million. Note that the company has a market cap of $21 billion, so this offering would constitute roughly 2% of the total cap.
BioNTech stock traded up about 6% to $93.83 on Tuesday, in a 52-week range of $12.52 to $105.00. The consensus price target is $55.39.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
